Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Piperidines

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514277000 - Hetero ring is six-membered consisting of one nitrogen and five carbon atoms

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514317000 Additional ring containing 873
514316000 Plural piperidine rings 55
Entries
DocumentTitleDate
20090298877Salts of creatine imino sugar amides - The present invention relates to stable salts of creatine imino sugar amides and an inorganic or organic acid endowed with enhanced nutritional and/or therapeutical efficacy in respect to their individual effects and to solid compositions containing such salts, particularly suited to oral and parenteral administration. Methods of preparation and use of these compositions are also provided.12-03-2009
20090069375DEUTERIUM-ENRICHED MIGLUSTAT - The present application describes deuterium-enriched miglustat, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-12-2009
20090192192INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA - The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of bacterial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.07-30-2009
20100113517METHOD FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONES - The present invention provides a method treating a patient with Fabry disease by determining whether there is an improvement of a surrogate marker that is associated with Fabry disease following administration of a specific pharmacological chaperone of α-galactosidase A. The method includes administering an effective amount of 1-deoxygalactonojirimycn to the individual, wherein the 1-deoxygalactonojirimycin binds to alpha-galactosidase A in an amount effective to increase activity of the alpha-galactosidase A. The present invention also provides a method for monitoring and increasing a therapeutic response of a patient with Fabry disease following administration of a specific pharmacological chaperone of α-galactosidase A by evaluating the effect on the cytoplasmic staining pattern of a cell from the patient, wherein detection of a staining pattern in the cell that is similar to the staining pattern in a cell from a healthy individual indicates that the individual with Fabry disease is a responder.05-06-2010
20130079368SKIN IMPROVING DERMO-COSMETICS - Provided is a dermo-cosmetic composition to improve rough skin that: improves chapped or dry skin, particularly roughened cuticles; improves skin texture; results in smooth skin; and has excellent safety, stability and feel. The disclosed dermo-cosmetic is characterised by having: (A) one or more of D-amino acids, their salts and derivatives; and (B) a swollen material prepared by swelling one or more of non-emulsifying cross-linked silicone with an oil which is in a liquid form at room temperature.03-28-2013
20130040990SYNTHESIS OF DGJNAc FROM D-GLUCURONOLACTONE AND USE TO INHIBIT ALPHA-N-ACETYLGALACTOSAMINIDASES - A convenient and scalable synthesis of DGJNAc ID from D-glucuronolactone in an overall yield of 20% is provided. DGJNAc is the first highly potent and specific competitive inhibitor of GalNAcases. DGJNAc ID is also a competitive inhibitor of -hexosaminidases. Synthesis and activity of L-DGJNAc IL is also shown. The use of DGJNAc as a potent and specific inhibitor of GalNAcases will allow useful investigation and treatment of a number of diseases, including Schindler Disease.02-14-2013
20090156637BUTYROPHENONES AND SIGMA-1 RECEPTOR ANTAGONISTS PROTECT AGAINST OXIDATIVE-STRESS - The present invention includes compositions and methods for the protection of one or more central nervous system cells from trauma, when administered before, during or after the trauma, wherein the composition includes an effective amount of a butyrophenone, e.g., a 1-linked phenyl butyrophenone that is electronegative along the butyl chain and/or a Sigma-1 receptor antagonist.06-18-2009
20090118330Diurea derivatives - The present invention relates to novel diurea derivatives that block intracellular signal transduction and thereby inhibit the production of pro-inflammatory cytokines, especially interleukin-2 (IL-2) and/or induce apoptosis in activated T-cells. It further discloses such a compound for use as a medicament, the use of said compound for the manufacturing of a medicament for the treatment of immune disorders which benefit from inhibition of production of IL-2 and other pro-inflammatory cytokines and/or induction of apoptosis in activated T-cells, a pharmaceutical composition comprising said compound and a method of treatment comprising administration of a pharmaceutically effective amount of said compound.05-07-2009
20110015226Treatment of Energy Utilization Disease - Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon.01-20-2011
20110130421Methods and Compositions for the Treatment of Chronic Renal Hypertension - Methods and compositions for the treating chronic renal hypertension in a subject comprising administering a therapeutically effective amount of at least one nitroxide-containing composition to the subject, particularly 4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl (Tempol).06-02-2011
20090253742MARASMIUS ANDROSACEUS L.ES FR EXTRACT, PIPERIDONE DERIVATIVE, AND THEIR USE FOR THE PREPARATION OF ANTIHYPERTENSIVES - The present invention relates to 10-08-2009
20090239907METHODS AND COMPOSITIONS FOR TREATING FISH DISEASES - Therapeutic and prophylactic treatments of aquatic species and aquatic diseases through the controlled introduction of a heterocyclic N-halamine into an aquatic habitat.09-24-2009
20130023560METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRON TOXICITY - Methods and compositions for the treatment of iron toxicity using nitroxides, particularly 4-hydroxy-2,2,6,6-tetramethyl-01-24-2013
20100081689Methods and Compositions for the Treatment of Iron Toxicity - Methods and compositions for the treatment of iron toxicity using nitroxides, particularly 4-hydroxy-2,2,6,6-tetramethyl-04-01-2010
20100113518METHODS OF USING ANTI-INFLAMMATORY COMPOUNDS - The invention relates to the use of 3-(2′,2′-dimethylpropanoylamino)-tetrahydropyridin-2-one for preparing a medicament intended to prevent or treat inflammatory disorders.05-06-2010
20100099707METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION - Pulmonary arterial hypertension in a mammal can be prevented or treated using combined 5-HT2A and 5-HT2B receptor antagonist. The antagonists can be present in a single compound or in two separate compounds04-22-2010
20110172271Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease - The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.07-14-2011
20090042937NITROXIDES FOR USE IN TREATING OR PREVENTING AMYLOID-RELATED DISEASES - Phamaceutical compositions are provided that are useful in treating amyloid protein-related diseases such as Alzheimer's disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that downregulates one or more genes related to the amyloid-related disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of amyloid protein-related diseases. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the amyloid protein-related disease is Alzheimer's disease. In a preferred embodiment, the downregulated genes are genes related to inflammation or oxidative stress.02-12-2009
20110207775AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT VESICLE-FUSING ATPASE ACTIVITY - The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect vesicle-fusing ATPase; a method for assaying pesticidal activity of a test substance, which comprises measuring the activity of a vesicle-fusing ATPase in a reaction system in which the vesicle-fusing ATPase contacts with a test substance, and the like.08-25-2011
20100324089Anti-inflammatory composition - The invention relates to 3-(2′,2′-dimethylpropanoylamino)-tetrahydropyridin-2-one, and its pharmaceutical compositions and its use for preparing a medicament intended to prevent or treat inflammatory disorders.12-23-2010
20120295937NITROXIDE THERAPY FOR THE TREATMENT OF VON HIPPEL - LINDAU DISEASE (VHL) AND RENAL CLEAR CELL CARCINOMA (RCC) - The invention provides therapeutic methods that include administering a stable nitroxide to a subject that has, is suspected to have, or is at risk for having a condition associated with reduced VHL or elevated HIF-2α.11-22-2012
20080269285Novel Compounds of the Family of Iminosugars, Uses Thereof for Trewating Lysosomal Diseases, and Method for Preparing Same - The invention concerns the use of a compound of general formula (I) wherein: R10-30-2008
20100160375METHODS AND COMPOSITIONS FOR TREATING INFECTIONS COMPRISING A LOCAL ANESTHETIC - The present invention is directed to a drug depot useful for reducing, preventing or treating an infection in a patient in need of such treatment. The drug depot includes a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof. The drug depot is administered at a site to reduce, prevent or treat an infection. The drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at the site and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days at the site.06-24-2010
20090176830TARTRATE SALT OF ISOFAGOMINE AND METHODS OF USE - A novel tartaric acid salt of Isofagomine (Isofagomine tartrate) that can be used for the treatment of Gaucher disease is provided. The invention also provides a crystalline form of isofagomine tartrate, method for preparing the salt, a pharmaceutical composition containing the salt, and a method of treating Gaucher disease.07-09-2009
20090062339COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF NICOTINE ACETYLCHOLINE RECEPTORS - The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro.03-05-2009
20080319015Insect Repellent Mixture - The present invention relates to the use of an insect repellent, preferably selected from the group 2-(2-hydroxyethyl)-1-methylpropyl 1-piperidinecarboxylate, N,N-diethyl-3-methylbenzamide, dimethyl phthalate, butopyronoxyl, 2,3,4,5-bis(2-butylene)-tetrahydro-2-furaldehyde, N,N-diethylcaprylamide, N,N-diethylbenzamide, o-chloro-N,N-diethylbenzamide, dimethyl carbate, di-n-propyl isocinchomeronate, 2-ethylhexane-1,3-diol, N-octylbicycloheptenedicarboximide or piperonyl butoxide, particularly preferably 2-(2-hydroxyethyl)-1-methylpropyl 1-piperidinecarboxylate, as action enhancer for a second insect repellent, to corresponding compositions, and to the preparation thereof.12-25-2008
20080319014Nitroxides for Use in Treating or Preventing Diabetes - Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of diabetes. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl).12-25-2008
20090062338NITROXIDES FOR USE IN TREATING OR PREVENTING CARDIOVASCULAR DISEASE - Pharmaceutical compositions are provided that are useful in treating cardiovascular disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cardiovascular disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of cardiovascular disease. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the cardiovascular disease is myocardial infarction.03-05-2009
20090209581NITROXIDES FOR USE IN TREATING OR PREVENTING IMMUNOLOGICAL DISEASES - Pharmaceutical compositions are provided that are useful in treating immunological diseases. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of a gene related to an immunological disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of immunological disease. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl); the gene is one of glucocorticoid-induced leucine zipper, collagen type I alpha 1, and complement component 6; and the immunological disease is Graves' disease, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-independent diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformus, vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, myasthenia gravis, multiple sclerosis, Guillain-Barre syndrome, stiff-man syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic lupus erythematosus, rheumatoid arthritis, systemic necrotizing vasculitis, Wegener's granulomatosis, antiphospholipid syndrome, Sjögren's syndrome, scleroderma, accelerated graft arteriosclerosis, graft-versus-host disease, Crohn's disease, or tuberculosis.08-20-2009
20090247580NITROXIDE RADIOPROTECTOR FORMULATIONS AND METHODS OF USE - Pharmaceutical compositions useful in preventing and treating negative side effects accompanying radiotherapy are disclosed. More particularly, new formulations that can be applied to the skin and mucous membranes of patients undergoing radiotherapy and methods of using these formulations are disclosed.10-01-2009
20100197731 KIND OF PIPERPHENTONAMINE HYDROCHLORIDE LYOPHILIZED POWDER FOR INJECTION AND PREPARATION AND USE THEREOF - A kind of piperphentonamine hydrochloride lyophilized powder for injection and a preparation method thereof. The injection is prepared by one portion of piperphentonamine hydrochloride, 2.5-30 parts of excipient and 400-600 parts of water for injection with pH 1.5-5.5 via freeze-drying. The excipient is mannitol, dextran, lactose, saccharose, polyethylene glycol, poloxamer, glycine, etc.; It is preferred that the injection comprises one part of piperphentonamine hydrochloride, 10 parts of mannitol and 500 parts of water for injection with pH 2.0-3.0. The product is prepared by adding said piperphentonamine hydrochloride and excipient into water for injection, heating at 40° C.-90° C., ultrasonic dissolving, degerming, individually packing, pre-freezing and multistage drying, and packaging. Individually packing into a tubular glass bottle with brown color is preferred. The appearance, color & luster and solubility of the injection are excellent, the stability is good and with long storage period. The invention also provides the uses of the injection in the preparation of a medicament for treatment of heart failure and/or cardioprotection.08-05-2010
20100222384Iminosugars and methods of treating arenaviral infections - Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Arenaviridae family using iminosugars, such as DNJ derivatives.09-02-2010
20100222385SELECTIVE ABLATION OF PAIN-SENSING NEURONS BY ADMINISTRATION OF A VANILLOID RECEPTOR AGONIST - The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons.09-02-2010
20100222386SUBSTITUTED PIPERIDINES - A novel class of substituted piperidines, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.09-02-2010
20100240700PROPHYLACTIC PRETREATMENT WITH ANTIOXIDANTS - Methods, compositions, and uses for pre-treating patients who are susceptible to ischemia, including stroke, with nitroxides, in order to prevent or ameliorate the effects of stroke or other ischemic disease.09-23-2010
20090036486COMPOSITION - The invention relates to the use of 3-(2′,2′-dimethylpropanoylamino)-tetrahydropyridin-2-one for preparing a medicament intended to prevent or treat inflammatory disorders.02-05-2009
20110034510ENANTIOMER-ENRICHED ALPHA-,OMEGA-AMINO ALCOHOL DERIVATIVES, THEIR PRODUCTION AND USE AS INSECT- AND MITE-REPELLING AGENTS - The invention relates to an insect- and mite-repelling agent, characterized by a content of at least one substituted, enantiomer-enriched α-,ω-amino alcohol derivative of formula (1) wherein X represents hydrogen, COR02-10-2011
20100137365Long chain N-alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C06-03-2010
20110086879CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS - The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.04-14-2011
20100056572COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE - Provided herein are piperidine alkaloids and uses thereof in neurological disorders and physical enhancement applications.03-04-2010
20100063090Composition for Repelling and Deterring Vermin - The invention describes essentially a non-therapeutical process for deterring vermin, which is based on the usage of the largely known beta amino-alcohol derivatives of formula (I), as defined herein before. Furthermore, it describes the corresponding vermin-deterring compositions which contain these substances as the active ingredient, compounds of the formula (I) for the preparation of vermin-deterring compositions, and the use of compounds of formula (I) in the defense against vermin. Thus, the invention describes how and in which form the compounds of the formula (I) or their acid addition salts are used to deter vermin from materials, places or warm-blooded animals.03-11-2010
20110098319FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY - The invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, useful for all the known clinical applications of the latter, which show physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterize butyrate. The new compounds are amide derivatives which can be synthesized by reaction of the corresponding fatty acid halide with a naturally occurring amino acid, phenylalanine or a suitable derivative thereof, and which are in a poorly hygroscopic, easily weighable form, stable to acids and alkalis and able to release the acid at the small and large bowel level in a constant manner over time. They do not have disagreeable odors and are practically tasteless, thus allowing the manufacture of preparations for oral administration also suitable for the therapy of chronic diseases and in the pediatric field.04-28-2011
20110212996METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES - The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.09-01-2011
20110152319METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES - The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.06-23-2011
20100261753METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM - The present invention provides methods for preventing and/or treating degenerative disorders of the central nervous system using 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.10-14-2010
20110257226HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF - There is provided a halogen-containing organosulfur compound having a controlling effect on arthropod pests represented by the formula (I): wherein m represents 0, 1 or 2; n represents 0, 1 or 2; A represents an optionally substituted 3- to 8-membered saturated heterocyclic group; Q represents a fluorine atom or a C1-C5 haloalkyl group having at least one fluorine atom; R10-20-2011
20100179188NITROXIDE RADICAL AS TREATMENT FOR NEURODEGENERATION - A method of treating or preventing neurodegeneration in a mammal comprising administering to the mammal an effective amount of a stable nitroxide radical, such as Tempo07-15-2010
20090012120Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines - An ylide-based aza-Payne rearrangement of 2,3-aziridin-01-08-2009
20120041025Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof - Compounds are provided that comprise dinitroso-derivatives of dihydrolipoic acid. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating various diseases and disorders, including angina, hypertension, diabetes, dyslipidemia, renal insufficiency, myocardial infarction, stroke, atherosclerosis, and the target organ damage that accompanies these various diseases and disorders, are further provided. The compounds are useful in improving vasodilation, reducing low-density lipoprotein oxidation, and reducing inflammation in a subject.02-16-2012
20100222383Iminosugars and methods of treating viral diseases - Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.09-02-2010
20080312279Compositions for Treating Fragile X and Other Disorders Methods of Use Thereof, and Screening for Compounds for Fragile X and Other Disorders - Methods of screening compounds, active compositions, pharmaceutical compositions, methods of treating disorders, methods of preventing disorders, and kits to screen a library of compounds, are disclosed.12-18-2008
20120065229INSECT REPELLENT COMPOSITION - The present invention relates to an insect repellent composition containing the following active insect-repellent material in a physiologically acceptable medium: at least 1-methylpropyl(2-(2-hydroxyethyl)piperidine-1-carboxylate, said active material being used with at least one copolymer of vinylpyrrolidone and of a linear alkyl, having at least 16 carbon atoms, as a film-forming agent.03-15-2012
20120046314NITROXIDES FOR USE IN TREATING OR PREVENTING NEOPLASTIC DISEASE - Pharmaceutical compositions are provided that are useful in treating or preventing neoplastic disease, such as cancer. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cancer. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of cancer. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl), and the cancer is esophageal cancer, hepatocellular carcinoma, colon cancer, prostate cancer, lung cancer, gastric carcinoma, renal cell carcinoma, bone cancer, breast cancer, cervical cancer, brain cancer, or a cancer associated with the tumor suppressor gene p53.02-23-2012
20080287494Transmucosal treatment methods in patients with mucositis - In accordance with the invention is an fentanyl-containing dosage form designed for transmucosal delivery which includes both an effervescent couple and a pH adjusting substance which can be administered to patients suffering from both pain and mucositis. Also provided is a method of treating pain in a patient having mild oral mucositis by administering a fentanyl-containing dosage form designed for transmucosal delivery.11-20-2008
20120115905Nitrone, Nitroso, and Nitroxide Spintraps and Spin Labels and Their Hydroxylamines - Nitrone, nitroso, and nitroxide spintraps and spin labels and their reduction products are claimed for the prevention and treatment of fibrocystic disease of breast, premenstrual dysphoric syndrome and associated symptomology, prevention and treatment of migraine headache, cyclic vomiting syndrome, rectal hemorrhoids, trigeminal neuralgia, peripheral vascular disease, influenza, peridontitis and gingivitis, herpes zoster, herpes simplex, and post-herpetic neuralgia.05-10-2012
20120309788Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases - The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones to increase the activity of gangliosidase and/or sialidase enzymes involved in ganglioside catabolism.12-06-2012
20110105560TREATMENT OF CNS DISORDERS ASSOCIATED WITH MUTATIONS IN GENES ENCODING LYSOSOMAL ENZYMES - Described is a method for treating an individual having a neurological disorder with an associated mutation or mutations in a gene encoding a lysosomal enzyme. Specifically, the individual is administered a specific pharmacological chaperone for the lysosomal enzyme which increases trafficking of the protein from the ER to the lysosome in neural cells, with or without concomitantly increasing enzyme activity in neural cells. Restoration of trafficking relieves cell stress and other toxicities associated with accumulation of mutant proteins. Restoration of enzyme activity relieves substrate accumulation and pathologies associated with lipid accumulation. In a specific embodiment, the neurological disorder is Parkinson's disease or parkinsonism which is associated with mutations in glucocerebrosidase.05-05-2011
20110184019Long chain N-Alkyl compounds and oxa-derivatives thereof - Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C07-28-2011
20120083509Synergistically active mixtures of alpha,omega-amino alcohol enantiomers, preparation thereof and use thereof in insect- and mite-repellent formulations - What are described are insect- and mite-repellent compositions comprising at least 2 enantiomers selected from the group of 1-[(S)-sec-butyloxycarbonyl]-2-(S)-(2-hydroxyethyl)piperidine (referred to hereinafter as S,S), 1-[(R)-sec-butyloxycarbonyl]-2-(R)-(+)-(2-hydroxyethyl) piperidine (referred to hereinafter as R,R), 1-[(S)-sec-butoxycarbonyl]-2-(R)-(+)-(2-hydroxyethyl) piperidine (referred to hereinafter as S,R), 1-[(R)-sec-butyloxycarbonyl]-2-(S)-(+)-(2-hydroxyethyl) piperidine (referred to hereinafter as R,S), excluding the racemate mixture thereof, a process for preparation thereof and the use thereof in insect- and mite-repellent formulations.04-05-2012
20120232111Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin - The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin—inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and further provides an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent comprises one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof. The external composition for skin comprises the one or more compounds selected from the group consisting of β-alanine derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent.09-13-2012
20100168165METHOD OF TREATING DISEASE INVOLVING MYELIN AND/OR AXONAL LOSS - Disclosed is a method of treating a disease involving myelin and/or axonal loss, such as a demyelinating disease, in a mammal comprising administering a compound of formula I07-01-2010
20130012539Compositions and Methods for Treating Lysosomal Disorders - The present invention provides compositions and methods for treating lysosomal disorders using a class of substituted imidazole derivatives or compounds.01-10-2013
20110160244PHENYLPIPERIDINE MODULATORS OF MU-OPIOID RECEPTOR - The present invention relates to new phenylpiperidine modulators of μ-opioid receptors, pharmaceutical compositions thereof, and methods of use thereof.06-30-2011
20130172385ANTHELMINTICS FOR PREVENTING PARASITIC INFECTIONS IN HUMANS AND ANIMALS - The present invention relates to compositions comprising certain active compounds which are suitable as repellents, and to their use for preventing an infection of humans or of animals by the infectious states of parasitic flatworms (platyhelminths).07-04-2013
20080234320CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES - The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.09-25-2008
20080214608New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments - This invention relates to new generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, to their optical isomers, diastereomers or enantiomers, as well as pharmaceutically acceptable salts, hydrates, prodrugs, polymorphs and pseudopolymorphs thereof, to their preparation, to their compositions and to their use.09-04-2008
20110269795USE OF GLUCOSIDASE INHIBITORS FOR THERAPY OF MUCOVISIDOSIS - A method provides for the use of glycosidase inhibitors selected from compounds of general formula (1), wherein R11-03-2011
20130116282BUCKWHEAT EXTRACT ENRICHED IN D-FAGOMINE - The buckwheat extract comprises a extract of buckwheat which are enriched in 05-09-2013
20130150405IMINOSUGARS AND METHODS OF TREATING TOGAVIRAL DISEASES - Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Togaviridae family using iminosugars, such as DNJ derivatives.06-13-2013
20120283290QUANTITATION OF GL3 IN URINE - The present invention is directed to the quantitation of GL3 in human urine which can be used for the diagnosis of Fabry disease as well as for the assessment of treatment efficacy thereof.11-08-2012
20110312997Inhibition of WDR5 Interaction with Its Binding Partners - Peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed.12-22-2011

Patent applications in class Piperidines

Patent applications in all subclasses Piperidines